Moderna Therapeutics Named the No. 3 Top Employer by Science Magazine
Cambridge, Mass., October 27, 2016 — Moderna Therapeutics, a clinical stage biotechnology company pioneering messenger RNA (mRNA) Therapeutics™ to create a new generation of transformative medicines for patients, today announced that Science and Science Careers has recognized Moderna as one of the biopharmaceutical industry’s top employers for the second consecutive year. Rankings are determined by Science and Science Careers’ annual Top Employer Survey, which polls employees across the globe in biotechnology, biopharmaceutical, pharmaceutical and related industries to rate companies on various key characteristics to arrive at a list of the 20 best employers. Moderna ranked #3 this year, moving up four spots from the 2015 Top Employer survey.
“We are very proud to be recognized as a top employer in the biopharmaceutical industry by Science for the second year in a row. Doing great science is necessary to create great medicines. A company cannot do great science without the right work environment and culture,” said Stéphane Bancel, CEO at Moderna. “We are very grateful to have such an exceptional group of scientists and industry professionals here at Moderna. This team is so committed to deliver on the promise of mRNA science for patients. They thrive on challenges and creative problem-solving, embody the spirt of collaboration, and share an unwavering focus on quality, integrity and respect. This team is relentless. We look forward to growing our team and continuing to hire best-in-class industry professionals who share our goal of addressing unmet medical needs by advancing mRNA medicines through scientific innovation.”
Ranked among a field of some of the industry’s most notable companies, Moderna was exemplary in three of the key driving characteristics of top employers, as identified by Science and Science Careers, including Innovative Leader in the Industry, Treats Employees with Respect and Has Clear Vision.
The rankings will appear in the October 28, 2016, print issue of Science, and are currently available online at ScienceCareers.org.
Science and Science Careers’ web-based survey includes results from 5,984 responses from readers of Science, as well as other survey invitees. The survey took place in the spring of 2016. Survey participants came from North America, Europe and Asia/Pacific Rim, with 93 percent working in biotechnology, biopharmaceutical and pharmaceutical companies. Rankings were determined by an independent research firm that analyzed survey responses rating companies based on 23 characteristics including a research-driven environment, easy adaptation to change and financial strength.
About Moderna Therapeutics
Moderna is a clinical stage pioneer of messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA drugs through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures are: Onkaido, focused on oncology, Valera, focused on infectious diseases, Elpidera, focused on rare diseases, and Caperna, focused on personalized cancer vaccines. Founded by Flagship VentureLabs™, Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca, Alexion Pharmaceuticals, Merck and Vertex Pharmaceuticals. To learn more, visit www.modernatx.com.